ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Down 43.3% in March

ReShape Lifesciences Inc. (NASDAQ:RSLS) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 428,700 shares, a decline of 43.3% from the February 29th total of 756,200 shares. Based on an average trading volume of 996,600 shares, the short-interest ratio is currently 0.4 days. Currently, 2.1% of the company’s shares are short sold.

Hedge Funds Weigh In On ReShape Lifesciences

A number of large investors have recently added to or reduced their stakes in the company. State Street Corp bought a new position in ReShape Lifesciences in the first quarter valued at $33,000. BlackRock Inc. grew its position in ReShape Lifesciences by 200,252.9% in the first quarter. BlackRock Inc. now owns 34,060 shares of the medical device company’s stock valued at $88,000 after purchasing an additional 34,043 shares in the last quarter. Renaissance Technologies LLC bought a new position in ReShape Lifesciences in the second quarter valued at $26,000. Sabby Management LLC bought a new position in ReShape Lifesciences in the first quarter valued at $192,000. Finally, Armistice Capital LLC bought a new position in ReShape Lifesciences in the third quarter valued at $64,000. Institutional investors own 22.06% of the company’s stock.

ReShape Lifesciences Trading Down 0.1 %

RSLS traded down $0.00 during trading on Thursday, hitting $0.18. The company had a trading volume of 634,572 shares, compared to its average volume of 863,482. The firm’s 50-day moving average price is $0.18 and its 200 day moving average price is $0.27. ReShape Lifesciences has a one year low of $0.14 and a one year high of $4.10.

About ReShape Lifesciences

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation.